US Patent 11123289 Rapamycin for the treatment of lymphangioleiomyomatosis

Patent 11123289 was granted and assigned to AI Therapeutics on September, 2021 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Current Assignee

OrphAI Therapeutics

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

11123289

Date of Patent

September 21, 2021

Patent Application Number

20191126

Date Filed

November 26, 2019

Patent Citations Received

‌

US Patent 11648199 Inhalable rapamycin formulation for treating age-related conditions

‌

US Patent 11491143 Inhalable rapamycin formulation for the treatment of pulmonary hypertension

Patent abstract

The present invention relates to methods and compositions for treating lymphangioleiomyomatosis in a human subject in need of such treatment. The methods comprise administering to the subject via inhalation an aerosol composition comprising rapamycin or a prodrug or derivative (including analog) thereof.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11123289 Rapamycin for the treatment of lymphangioleiomyomatosis

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API